Mencucci Rita, Boccalini Carlotta, Caputo Roberto, Favuzza Eleonora
From the Department of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.
From the Department of Surgery and Translational Medicine, Eye Clinic, University of Florence, Florence, Italy.
J Cataract Refract Surg. 2015 Aug;41(8):1699-704. doi: 10.1016/j.jcrs.2014.12.056.
To evaluate the efficacy and safety of using sodium hyaluronate 0.1% and carboxymethylcellulose 0.5% artificial tears for ocular discomfort and tear-film stability in eyes after cataract surgery.
Twenty ophthalmic centers in Italy.
Prospective randomized case series.
This study enrolled patients scheduled for unilateral cataract surgery. After surgery, patients received artificial tears and a topical steroid-antibiotic (study group) or topical steroid-antibiotic alone (control group) and were assessed postoperatively at 1 and 5 weeks. Outcome measures were tear breakup time (TBUT), ocular surface disease index (OSDI), frequency of dry-eye symptoms evaluated using a visual analog scale (VAS), and corneal fluorescein staining.
The study comprised 282 patients. At 5 weeks, the mean TBUT was statistically significantly higher in the study group than in the control group (P = .0003). The mean OSDI score statistically significantly improved in both groups from 1 to 5 weeks (P < .0001 for both groups); however, there was no statistically significant difference between the groups at these timepoints. The artificial tears statistically significantly improved VAS-assessed dry-eye symptoms in the study group compared with the control group at 5 weeks (P < .001). The mean corneal fluorescein staining was significantly reduced in the study group compared with the control group at 5 weeks (P = .002 versus P = .05, respectively). No treatment-related adverse events were reported.
Sodium hyaluronate 0.1% and carboxymethylcellulose 0.5% ophthalmic solution was effective and well tolerated in reducing dry-eye disease symptoms and improving the clinical outcome after cataract surgery.
No author has a financial or proprietary interest in any material or method mentioned.
评估0.1%透明质酸钠和0.5%羧甲基纤维素人工泪液对白内障术后眼部不适和泪膜稳定性的疗效及安全性。
意大利的20个眼科中心。
前瞻性随机病例系列研究。
本研究纳入计划行单侧白内障手术的患者。术后,患者接受人工泪液和局部用类固醇 - 抗生素(研究组)或仅接受局部用类固醇 - 抗生素(对照组),并在术后1周和5周进行评估。观察指标包括泪膜破裂时间(TBUT)、眼表疾病指数(OSDI)、使用视觉模拟量表(VAS)评估的干眼症状频率以及角膜荧光素染色。
该研究共纳入282例患者。在5周时,研究组的平均TBUT在统计学上显著高于对照组(P = 0.0003)。两组的平均OSDI评分从1周时到5周时在统计学上均有显著改善(两组P均<0.0001);然而,在这些时间点两组之间无统计学显著差异。与对照组相比,在5周时人工泪液使研究组中VAS评估的干眼症状在统计学上有显著改善(P < 0.001)。在5周时,研究组的平均角膜荧光素染色较对照组显著降低(分别为P = 0.002和P = 0.05)。未报告与治疗相关的不良事件。
0.1%透明质酸钠和0.5%羧甲基纤维素眼药水在减轻干眼疾病症状和改善白内障术后临床结局方面有效且耐受性良好。
没有作者对文中提及的任何材料或方法拥有财务或专利权益。